The public registers hold a second record for Sms Lifesciences India. The fuller profile, with 41 active US DMFs and 22 valid CEPs, is at SMS Pharmaceuticals. Figures on this page cover only this record.
Sms Lifesciences India is an API manufacturer based in India. It holds 4 active US drug master files across a filed portfolio of 4 molecules. Customs aggregates show $12.7M of exports covering 249 molecules to 39 destinations in 2025.
| Molecule | Regulators | Docs |
|---|---|---|
| Cimetidine | US FDA | 1 |
| Famotidine | US FDA | 1 |
| Furosemide | US FDA | 1 |
| Minoxidil | US FDA | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $12.7M | 39 |
| 2024 | Not reported | $13.9M | 39 |
| 2023 | Not reported | $15.7M | 37 |
| 2022 | Not reported | $14.4M | 39 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Sms Lifesciences India comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.